Cancer screening and early detection efforts have been partially successful in reducing incidence and 10 mortality but many improvements are needed. Although current medical practice is mostly informed by 11 epidemiological studies, the decisions for guidelines are ultimately made ad hoc. We propose that quantitative 12 optimization of protocols can potentially increase screening success and reduce overdiagnosis. Mathematical 13 modeling of the stochastic process of cancer evolution can be used to derive and to optimize the timing of 14 clinical screens so that the probability is maximal that a patient is screened within a certain "window of 15 opportunity" for intervention when early cancer development may be observable. Alternative to a strictly 16 empirical approach, or microsimulations of a multitude of possible scenarios, biologically-based mechanistic 17 modeling can be used for predicting when best to screen and begin adaptive surveillance. We introduce a 18 methodology for optimizing screening, assessing potential risks, and quantifying associated costs to healthcare 19 using multiscale models. As a case study in Barrett's esophagus (BE), we applied our methods for a model 20 of esophageal adenocarcinoma (EAC) that was previously calibrated to US cancer registry data. We found 21 optimal screening ages for patients with symptomatic gastroesophageal reflux disease to be older (58 for 22 men, 64 for women) than what is currently recommended (age > 50 years). These ages are in a cost-effective 23 range to start screening and were independently validated by data used in current guidelines. Our framework 24 captures critical aspects of cancer evolution within BE patients for a more personalized screening design.
A) The goal of early detection and prevention is to perform an initial screen on individuals within a larger population after premalignant changes reside in cells but before incidental cancer occurs in order to intervene. After an initial screen at time t * s , adaptive recommendations for patient-specific follow-up surveillance can iteratively account for the heterogeneity in a screened population. B) Somatic evolution of stem cell lineages since birth leads to stochastic trajectories (certain symmetric division examples shown on tree nodes) that accumulate mutations and may be selected for advantageous phenotypes. For example, within an at-risk patient's esophagus, normal squamous epithelium may transform to a columnar BE segment with rate ν(t). Stochastic appearance of premalignant P cells can occur (e.g., after 'two-hit' gene inactivation of TP53 in a cancer-promoting miroenvironment), which can then undergo clonal expansion described by birth-death-mutation processes. Malignant cells M that are initiated, in turn, may undergo clonal expansions or go extinct. Clinical detection of M clones that do not go extinct may occur through a size-based detection process with rate ρ. C) Criteria for optimal screening strategies can be formally defined using probability distributions in (A) for the timescales that characterize certain stages of carcinogenesis (see Text for details). expected to be highly heterogeneous within the population based on individual screening outcome. To account 120 for this heterogeneity along with the temporal effects of screening (e.g., different prognoses resulting from esophageal adenocarcinoma. Thus, this method allows for random truncation due to death from other causes.
For the general weighting w > 0 for events A and B, we compute the criteria defined as,
In these methods we will derive optimal screen times t * s by maximizing Eq.
(3) and refer to these t * s as the 162 screening times that satisfy the optimality criterion for a given value of weighting factor w,
Quantifying risk for screening times. To perform a constrained optimization problem with additional risks 164 incorporated, we quantify a penalty for certain screening times by introducing an equation for the risk R B (t * s ) 165 that some later event B has already occurred given some optimal screening time t * s ,
For cancer screening guideline decision-making, we can increase the weight w in Eq.
(3) to find optimal time 167 t * s such that R B (t * s ) < , where is a threshold parameter for the allowable amount of risk of event B.
168
Alternatively, if the risk of possibly allowing an undesirable event B before a proposed time t * s is too small 169 to be of considerable worry, we reduce the weight w assigned to event B and thus raise the risk of event B 170 to an appropriate, or tolerable, level.
Random variables for screening outcomes. The random variables of interest that represent four clinical points 181 of the multistage process are:
where ν(t) is the rate of precursor development. As has also been applied recently in case studies of gastric, lung, and oral cancers [29] , we allow ν(t) to be time-dependent to allow straightforward incorporation of etiological agent prevalence that affect initiation rates in a population. For BE, we model the density f BE (t) 187 with rate ν(t) given as a function of the prevalence of symptomatic gastroesophageal reflux disease (GERD) 188 at age t, 189 ν(t) = ν 0 ((1 − p sGERD (t)) + RR · p sGERD (t)),
where p sGERD (t) is the prevalence of GERD symptoms at age t, RR is the relative risk of BE initiation due 190 to exposure to GERD symptoms, and ν 0 is a positive constant.
191
Unlike the one-time occurence for T A and T C , the detectability of premalignancy (T d P (t)) and malignancy 192 (T d M (t)) require specific definitions for appropriate binary random variables. If we designate these times 193 to be the time of initiation or malignant transformation of a cell regardless of its fate (i.e., the ancestor 194 to a clonal progeny that eventually goes extinct or that survives), we may derive analytical probabilities 195 with first-passage time for continuous random variables T P and T M , respectively, using master equations. 196 However, it is more clinically relevant to define these random variables as binary outcomes for detectable 197 clones at the time of screening t s . In the derivations of our screening windows, the probability of detection 
201
In the Results below, we assign these binary detection variables the value 1 if a clone born at time s is non-202 extinct at time t s (size of clone is ≥ 1) and 0 otherwise. In the case of EAC, this "perfect sensitivity" definition 203 will be useful as progressively better high-resolution imaging technologies and minimally invasive sampling 204 devices are tested in trials in BE [16, 30] and used in future clinical practice. Lastly, we present the two survival 205 functions that will appear throughout the mathematical derivations:
is the survival function for the multistage clonal expansion model 207 of interest after precursor A onset and S C (t) is the survival function for the full model (S EAC (t) for the 208 MSCE-EAC model, see Supplementary Methods 1).
209
Strategies for optimizing initial screening ages 210 Strategy 1: Optimization of precancerous yield before cancer. This strategy for initial screening success aims to maximize the probability that an individual has developed the precursor of interest before the time of screening but has not yet developed clinical cancer ( Figure 1C , beige),
Thus to satisfy the optimality criterion in this scenario for weighting parameter w described by Eq.
(3), we 211 solve for the optimal screening age t * s (Eq. (4)) as follows
Strategy 2: Optimization of precancerous yield before dysplasia. This strategy for initial screening success 213 aims to maximize the probability that an individual has developed the precursor before the time of screening 214 but has not yet developed a detectable premalignant clone (e.g., dysplasia, Figure 1C , light pink),
Then solving the optimality criterion for weighting parameter w on dysplasia development, we solve for this optimal screening age t * s as follows,
We utilize the filtered Poisson process (FPP) approach to analytically solve for Pr T d P (t s ) = 1|T A = τ 216 in the integrand (see Supplementary Methods 2 for derivation). Thus together with A onset distribution in 217 Eq. (5) and mortality risk, we have the analytical solution for optimal screening age in Eq. (8).
219
Strategy 3: Optimization of dysplasia yield before cancer. As a final example, we aim to maximize the 220 probability that an individual has developed detectable dysplasia before the time of screening but has not 221 yet developed a synchronous screen-detectable malignancy ( Figure 1C , dark pink),
222
Pr
Thus the optimal screening time t * s for Strategy 3 for specified w is given by,
Integrating over all possible onset times for precursor A, we can also derive the analytical solution for this 223 optimal screen time (full derivation in Supplementary Methods 3).
224
Metrics for assessing screening efficacy 225 Successful screening of future cancers cases. For screening effectiveness results, we define a successful diagnosis 226 function SD(t s ) for the probability of successful screening for future cancers before an age T f ,
Thus SD(t s ) is the proportion of patients who get cancer before T f , who biologically have A (undiagnosed) 228 before screening age t s . Here we distinguish T D , a random variable for patient-specific death, from T f , a 229 known constant time point (e.g., age 80) representing a set length of patient follow-up for comparison.
231
Overdiagnosis at screening age. Alternatively, OD(t s ) is the probability of overdiagnosis (OD), given by 232
Thus OD(t s ) is the proportion of patients who will not get cancer before age T f but who have A at time t s .
Proportion of over-screening in a positive-screen population. Another important quantity is the proportion 235 of positive screens at the time t s who will undergo needless, costly surveillance. We can reformulate this 236 proportion as a function with terms previously computed from OD(t s ) above and Strategy 1 (Eq. (6)),
Proportion of successful screening in a positive-screen population. Lastly, the fraction of those who will be a successful screen (SS), for whom surveillance may be life-saving due to early detection of small cancers that will form prior to symptomatic detection, can be considered the positive predictive value (PPV) of the screen. We can reformulate this proportion as the complementary conditional event of OS(t s ) above,
Comparing costs of different screening ages. To quantify the effects of different screening ages, we define a 238 cost function C(t s , T f ) for screening time t s and surveillance until an age T f . We aim to minimize the cost 239 function which incorporates needless surveillance of the over-screened population from age t s to age T f ,
Here we assume that over-treatment/over-surveillance costs are likely proportional to the fraction of over- (e.g., patient age, gender). In our proposed method for adaptive surveillance, mechanistic modeling of the 248 carcinogenesis process is assessed conditional on patient demographic/clinical features and detected stage of 249 progression (or lack thereof) at screening time t s1 to provide a more refined surveillance recommendation. 
We derive the optimal age (see Supplementary Methods 4 for full solution) for a next screening time as,
Outcome 2 (positive for precursor): associated cancer risk. After diagnosis, we can iteratively condition on 256 the screening/surveillance result at time t si , SR(t si ), and derive an optimal interval for the next surveillance 257 given some chosen outcome of interest to obtain t * si+1 . For Outcome 2 with no dysplasia/neoplasia detected, 258 the subsequent risk for cancer developing before a suggested next surveillance exam at time t s2 is,
In general, a physician will often have no way of knowing how long a patient has harbored undetected 260 cancer precursors in the body, only that onset occurred sometime before screening (T A < t s1 ). But if we could 261 measure this precursor onset time τ , then his/her associated cancer risk for next surveillance age t s2 would 262 be more specific than defined above and would be defined (see Supplementary Methods 4 for derivation) as, 
Previously calibrated parameter values reproduce population cancer incidence. The optimal screen design 268 methodology presented thus far is applicable to multistage models, in particular branching process disease 269 models with defined stages of clonal expansions occurring during carcinogenesis. In a case study for BE 270 screening presented here, we apply the optimality criteria defined above for the MSCE-EAC model specifically. mogorov equations for the stochastic multistage process described above and solved numerically via a system 275 of coupled ordinary differential equations (Supplementary Methods 1). Thus, one may infer rates of cellu-276 lar processes from cancer incidence data (see [25, 27] for model results using EAC incidence data from the 277 Surveillance, Epidemiology, and End Results (SEER 9) registry 1975-2010, with predicted trends to 2030).
278
For the quantitative Results in the use case below, we evaluate the equations defined in the above methods 279 using values for evolutionary variables previously estimated in [27] , provided in Supplementary Table S1 .
280

Results
281
Recommendations for risk-stratified Barrett's esophagus (BE) screening and surveillance regimes have 282 been proposed to optimize beneficial use of healthcare resources, but these have been limited in strata choices, including patient age), which were proposed by experts and deemed cost-effective [28] .
294
Instead, we applied our framework in the case of BE to obtain optimal screening and surveillance design 295 from theoretical predictions a priori. In our notation for this framework (Materials and Methods), we specif-296 ically refer to initial precursor development T A = T BE , the detection of premalignant (high grade dysplasia) 297 and preclinical malignant clones T d P (t s ) and T d M (t s ), respectively, and clinical cancer occurrence T C = T EAC .
299
Optimal ages to initialize screening in Barrett's esophagus. We first used the model to optimize the choice of 300 recommended age to start screening, rather than assuming age 50 as the threshold to begin screening across 301 risk groups as guidelines suggest currently (in all those that specify an age [31]). We applied Strategy 1 302 (Materials and Methods) for a single screen to maximize the probability that an individual has developed 303 Model estimates of optimal screening ages t * s and associated metrics for Strategy 1 (w = 1, see Materials and Methods) including successful diagnoses (SD) of future EAC cases, overdiagnoses (OD) of non-EAC cases, positive predictive value (PPV), and the risk of cancer occurring before the screening age recommendations for US persons, all races, born in 1950, stratified by sex and GERD symptom status. BE before the time of screening but has not yet developed clinical EAC, thus obtaining optimal screening 304 ages t * s defined in Eq. (7) for weight parameters w.
305
In line with current risk factors, we computed optimality criteria for timing of individuals screened for 306 BE stratified by age, sex, and GERD status (i.e., general population or symptomatic GERD population).
307 Figure 2 depicts the contour plots of these optimality criteria for individuals born in year 1950 along with the 308 optimal ages for each w (red lines). We sought ages by whole years for simplicity, in the way that guidelines 309 are formulated currently. For w = 1 (i.e., equal weighting of positive screen and safeguarding from cancer 310 before screening), the optimal screening times were (A) t * s = 64 years old for males, (B) t * s = 58 years old for 311 males with GERD symptoms (indicated by red diamonds), (C) t * s = 69 years old for females, and (D) t * s = 64 312 years old for females with GERD symptoms (indicated by red circles). In consistency with previous efficacy 313 and cost-effectiveness analyses of BE screening [16, 25, 27, 28] , we present results applied to the 1950 birth 314 cohort as a 'base case' study and note that screening optimization predictions are robust through modern 315 birth cohorts in a 50 year range (Supplementary Figure S2 ). This is consistent with previous BE prevalence 316 estimates at index endoscopy that found only a small secular age-specific trend in index BE prevalence in 317 white male GERD screenees but no trend in women across the calendar year period years 2000-2006 [34] .
318 Table 1 provides the optimal ages computed for stratified populations along with associated metrics of 319 efficacy. Optimal screening ages t * s defined in Eq. (7) HGD clones, we applied Strategy 2 in our optimization to obtain optimal screening times (see Eq. (8)).
328 Figure 3 depicts the contour plots of the optimality criteria for individuals born in 1950 stratified by age, 329 sex, and GERD status along with the optimal ages for each w (red lines). For w = 1 (i.e., equal weighting 330 of positive screen and safeguarding from HGD before screening), the optimal screening times were t * s = 59 331 years old for males and t * s = 65 years old for females, which are 5 and 4 years earlier for males and females, 332 respectively, than the optimal ages computed for the general population in Strategy 1. Interestingly, for the 333 symptomatic GERD population, there is no optimal time obtained for w = 1 because it is unfeasible to screen 334 early enough such that those with GERD and BE do not have any small HGD clones present. However, to 335 lessen the cost of having small HGD clones at time of screening in our optimization, we set w = 0.95 and The optimality criteria are plotted for given screening age ts between ages 10 and 119 and weighting parameters w ∈ [0, 1). Note, as the weighting factor increases the optimal screen age becomes earlier. The red line on the 2D contour plot denotes the optimal screening ages for all races combined, born in 1950.
found the same optimal ages for GERD patients as were found using Strategy 1. stratified by sex and presence of GERD symptoms as indicated in the endoscopy report [34] ( Figure 4A ).
344
First we directly compared the CORI prevalence with our model by computing the analogous conditional (14))) recapitulate CORI data for BE prevalence detected on index endoscopy in cancer-free individuals (dashed lines). B) Strategy 1 (single age results using Eq. (7) with w = 1, 95% confidence intervals shaded) incorporates both protection from previous cancer formation (missed cases) and all-cause mortality pre-screening time into optimal screening decision-making (green diamonds).
Pr[T
where this numerator was computed previously in Strategy 1 (see Eq. (6)).
348
This data independently validated the similar age trends predicted by our model (which was fit to SEER 349 incidence, irrespective of CORI) for these strata born in 1950 ( Figure 4A for w = 1). In only the case for the 350 highest risk group, our estimates of prevalence were found to be slightly greater than the published estimates analytically but furthermore an optimal criterion with Strategy 1, we can maximize the BE yield at any 360 continuous age t subject to a joint probability of being cancer-free and alive ( Figure 4B for and (2) how likely it would be that BE would be found at that age. 386 We optimized when to screen this individual again at a later age t s2 when he/she is most probable 387 to have developed BE by this time but not yet clinical cancer. Given a range of prior screening times 388 t s1 ∈ {45, 50, 58, 64, 69}, Figure 5 shows results for optimal subsequent screening times t s2 , where t s1 < 389 t s2 < 120. The black diamonds depict the optimal screen times t * s2 (see Eq. (12)) for this simulated cohort 390 (US population, all races, born in 1950). For our choices of t s1 in ascending order, we found that optimal 391 follow-up screens were (A) t * s2 = {73, 74, 76, 77, 78} for all males combined, (B) t * s2 = {72, 73, 75, 76, 77} for 392 GERD males, (C) t * s2 = {77, 78, 79, 81, 82} for all females combined, and (D) t * s2 = {76, 77, 79, 80, 81} for 393 GERD females. Thus, even though initial screening times may be over 20 years apart, the optimal range of 394 a follow-up screen at age t * s2 is only within a 5 year window.
395
Our prevalence figures for these are very close to those found in the CORI study for both genders [35] , 396 further validating our straightforward approach to assess public health questions that typically depend on 397 grouped, conditional empirical population data (alive, cancer-free) for prevalences rather than optimally 398 scheduled predictions of screening outcomes and yields based on continuous age. Importantly, we found that 399 the initial age of screening (rather than time since initial screening) affects the future probability of BE yield; 400 such information is not currently considered when clinicians decide whether certain GERD patients should 401 return to be re-screened. For example we found that, if initial screening took place for GERD males at age 402 58, there would be a 1% chance of a positive re-screen rather than 2 − 3% when screening first at age 50. Im-403 portantly, even this 1% will be mostly overdiagnoses as de novo BE is much less likely to have time to develop 
0.008
Screening time t s2 (age) Probability t s1 = 45 t s1 = 50 t s1 = 58 t s1 = 64 t s1 = 69 D) Females with GERD symptoms Figure 5 : Optimality criteria for Outcome 1 (negative for BE): Strategy 1. The optimality criteria for each choice of next screening time ts 2 , given prior screening age ts 1 ∈ {45, 50, 58, 64, 69} are denoted for weighting w = 1 (including typical case for current practice, ts 1 = 50, shown in dashed lines). Optimal re-screen times t * s 2 shown for all races, born in 1950 (diamonds), and for the risk group-specific optimal t * s 1 (dotted lines), were (A) t * s 2 = 77 for all males, (B) t * s 2 = 75 for GERD males, (C) t * s 2 = 82 for all females, and (D) t * s 2 = 80 for GERD females.
to EAC within the remainder of patient lifespan, thus further devaluing a re-screen after initial negative result.
406
Accurate cancer risk prediction depends on premalignant molecular age. In Outcome 2, a patient is found 407 to have BE but no neoplasia (HGD/malignancy) at screening time t s1 . Current guidelines suggest these 408 patients return for surveillance endoscopies every 3-5 years for the rest of their lives [32, 33] Sensitivity of predictions. Our multistage model was calibrated to population incidence data [27] and has 427 been previously tested to quantify the effects of perturbations in model parameters in Supplementary Table   428 S1 such as initiation and growth rates of dysplastic clones that reflect published premalignant prevalence 429 within BE (see details in [25, 38, 39] ). Similarly, in these analyses, we tested our model for risk-stratified 430 populations and found that our optimal timing predictions are robust to perturbations in parameters, as 431 calculated for optimal ages in a bootstrap analysis of 1,000 re-sampling iterations of the Markov chain Monte 432 Carlo (MCMC) posterior distributions for each calibrated parameter ( Figure 4B, shaded regions) . 433 We also considered 5 additional modern birth cohorts beyond the 1950 base case and found that: (1)
434
Optimal screening ages remain unchanged for males (GERD and general populations) born between 1950 and 435 2000, and (2) similar results to the base case were found for females such that optimal screening times t * s varied 436 between these cohorts by only 3 years in females with GERD and 2 years for the general female population 437 (Supplementary Figure S2) . For optimal choice of adaptive surveillance based on screening outcomes however, 438 we found that results will be sensitive to certain patient-specific parameters such as BE onset age and thus 439 these will be important to include in order to perform more personalized surveillance.
[ initial screen (such as detection of Barrett's esophahus (BE)). More refined adaptive recommendations for a 707 follow-up surveillance at patient-specific time t s2 can iteratively account for the heterogeneity in a screened 708 population (i.e., other factors that contribute to a patient being low risk (blue) versus high risk (red)). C) 709 Within the MSCE-EAC multi-type branching process framework in a single patient's esophagus, normal 710 squamous epithelium may transform to BE cells X at a random onset time with rate ν(t), followed by a 711 'two-hit' tumor initiation process with Poisson rates µ 0 (creating P * progeny), and µ 1 , which leads to the 712 stochastic appearance of premalignant progenitor P cells. Premalignant cells undergo a first clonal expansion 713 described by a birth-death-mutation process with cell division rate α P , cell death-or-differentiation rate β P , Figure S2 : Sensitivity analysis for optimal screening ages for birth cohorts 1960 -2000. We 721 found that the optimal ages for men of both risk strata remain unchanged from the base case results (birth 722 cohort 1950, Figure 4B ) with increasing birth cohort. Specifically, for men with GERD we found that 723 optimal screening age was t * s = 58 and for all men combined was t * s = 64 for all 5 additional birth cohorts 724 tested. For women, we found slight differences due to the flatter optimality criterion computed: optimal 725 initial screening ages were t * s = {62, 61, 60, 59, 59} for women with GERD, and t * s = {69, 68, 69, 67, 68} for all 726 women combined, for birth cohorts 1960, 1970, 1980, 1990, and 2000 , respectively, denoted by color.
727 Supplementary Tables   728   Table S1 : MSCE-EAC model biological parameters (rates per cell per year). Value (95% CI) Males Females ν 0 3.65 (3.19 − 4.13) × 10 −4 7.48 (4.87 − 10.29) × 10 −5 µ 0 (µ 1 ) 7.99 (6.38 − 9.83) × 10 −4 7.05 (6.13 − 12.25) × 10 −4 µ 2 4.54 (3.65 − 6.47) × 10 −5 6.89 (3.16 − 14.28) × 10 −5 g P,0 * 9.91 (9.28 − 10.99) × 10 −2 1.23 (1.06 − 1.35) × 10 −1 g 1 * 5.09 (2.75 − 5.90) × 10 −1 6.40 (2.16 − 8.44) × 10 −1 g 2 * 5.38 (4.83 − 5.72) × 10 −2 2.98 (2.47 − 3.44) × 10 −2 g 3 * 1912. 5 (1909.1 -1914.1) 1945.3 (1923.9 -1954.4 ) * Variables denoted with g are parameters of sigmoidal functions specific to a birth cohort and gender to obtain premalignant and malignant clonal proliferation rates, respectively, so that solving g P = α P − β P − µ 2 and g M = α M − β M − ρ obtains the parameters in Fig S1 (see [25] for explicit details).
Supplementary Methods
Multistage clonal expansion (MSCE) model survival functions 730
We first introduce the notation for the following random variables of the multi-type branching process The Chapman-Kolmogorov equations governing the transition probabilities for this multistage process include contributions from the initial Armitage-Doll type transition to BE, the two Poisson transitions to initiation, and the two birth-death-migration processes, all of which have been derived previously [13, 59, 60] . We begin with a method for solving for these generating functions using the Kolmogorov backward equations. Beginning with an active BE segment (BE), a single pre-initiated (P * ), premalignant (P ), or malignant (M ) cell at time τ only, we define the following generating functions Φ BE ,Φ P * , Φ P , or Φ M , respectively, The generating functions satisfy the following Kolmogorov backward equations
∂Φ BE (y BE , y 1 , y 2 , y 3 , z; τ, t) ∂τ = −µ 0 XΦ BE (y BE , y 1 , y 2 , y 3 , z; τ, t)[Φ P * (y 1 , y 2 , y 3 , z; τ, t) − 1]
∂Ψ(y BE , y 1 , y 2 , y 3 , z; τ, t) ∂τ = ν(τ )[Ψ(y BE , y 1 , y 2 , y 3 , z; τ, t) − Φ BE (y BE , y 1 , y 2 , y 3 , z; τ, t)]
To connect the cellular level description to the population level, we first solve for the overall survival function (for EAC cancer detection), starting at time 0, which in our notation is We will here denote Φ M (1, 0; τ, t) ≡ Φ M (τ, t), Φ P (1, 1, 0; τ, t) ≡ Φ P (τ, t), Φ P * (1, 1, 1, 0; τ, t) ≡ Φ P * (τ, t),
733
Φ BE (1, 1, 1, 1, 0 ; τ, t) ≡ Φ BE (τ, t), and Ψ(1, 1, 1, 1, 0; τ, t) ≡ Ψ(τ, t). A dot designates a first derivative with 734 respect to t. The hazard function, i.e., the rate at which cancer is detected in individuals who have not been 735 diagnosed before, is given by
For fixed t, this boundary value system of coupled PDEs can be converted into an initial value problem (IVP) with the change of variables u = t − τ , where u is the "running" time. This redefinition and equations hereafter follow the method used by Crump et al. [61] . Define the following variables for the new IVP:
Y 10 (0, t) = 0, and Y 2 (0, t) = −ρ. Then the equations to solve for our IVP are the following
These 10 coupled ODEs can be solved numerically to obtain the desired survival functions,
737
S M SCE (t) = Y 7 (t, t), S EAC (t) = Y 9 (t, t).
In the Results, we assigned binary detection variables the value 1 if a clone born at time s is non-extinct 738 at time t s (size of clone is ≥ 1) and 0 otherwise. In the case of EAC, this "perfect sensitivity" definition 739 will be useful as progressively better high-resolution imaging technologies and minimally invasive sampling 740 devices are tested in trials in BE [16, 30] and used in future clinical practice. For detectability based on this 741 non-extinction criterion at time of screening, we adopt the probability of detection with a binary outcome 742 variable for malignant clones with an unconditional birth-death-mutation size distribution (see Jeon et al.
743
[18] ). The forms of these are given by,
where
We obtain the analogous definition for p 2 (s, t s ) with P parameters for 746 the detection probability of premalignant clones -
where ζ P (s, t s ) = e (α P −β P )(ts−s) − 1 α P e (α P −β P )(ts−s) − β P .
As t s → ∞, p 2 (s, t s ) → 1 − β P /α P , which is the asymptotic probability of non-extinction.
749 2. Initial screen strategy 2 750 We aim to derive the optimal screening age t * s (Eq. (8) in Main Text)
Applying useful theory in multi-type branching processes for multistage models, we utilize the filtered Poisson process (FPP) approach [62, 63] ) to analytically solve for Pr T d P (t s ) = 1|T A = τ . Let N (σ, t s ) be the number of initiated P cells from a P * cell born at time σ that result in a detectable HGD clone at time t s
where N l (σ, t s , s l ) = 1 if initiation at time s l produces a detectable clone at time t s , and s l ≤ t s , with
where p 2 (s l , t s ) is defined in Eq. (37). Next let M (τ, t s ) be the number of preinitiated cells after BE onset at time τ that result in a detectable P clone at time t s . Then we have
where M i (τ, σ i , t s ) is binary and is equal to 1 if the preinitiated cell originting at time σ i after BE onset at time τ results in a detectable P clone at time t s , with τ ≤ σ i ≤ t s . Note that M i (τ, σ i , t s ) = 1 is equivalent to N (σ i , t s ) ≥ 1 which has the probability p 3 (σ i , t s2 ) = 1 − exp − ts σi µ 1 p 2 (s, t s )ds with p 2 (s, t s ) given by Eq. (37). Then M (τ, t s ) is a FPP such that
Thus together with A onset distribution in Eq. (5) and mortality risk, we have the analytical solution for optimal screening age in Strategy 2, given in Eq. (8).
753 3. Initial screen strategy 3
754
Here we derive the analytical solution for the optimal screening time for Strategy 3, given some weighting 755 w to avoid risk of co-existing malignant clones (Eq. (9) in Main Text),
The first integral in this difference was derived in Strategy 2 (see Eq. (38)). We solve for the probability in the integrand of the second integral with detectability given in Eq. (36) and Eq. (37) for malignant clones and HGD clones, respectively. Thus we seek an explicit formula for the integrand,
To derive the above probability, we must define C 1 , C 2 , C 3 , mutually exclusive scenarios of counts of initiations of different types. Scenario C 1 corresponds to the scenario that the P clone that is non-extinct at time t s is the ancestor of the non-extinct M clone at time t s . This is most commonly the case in the stochastic realizations since the bigger P clones that remain non-extinct at time of screening have the highest probability to have had µ 2 events (malignant transformation) occur since their initiation. Scenario C 2 accounts for a non-extinct P clone at time t s that, if it created any malignant progeny before time of screening, those malignancies went extinct. Scenario C 3 accounts for a non-extinct M clone at time t s whose ancestral P clone went extinct before time t s . Thus the probability we aim to derive accounts for either event C 1 or C 2 and C 3 together. For each of the three scenarios, we will use filtered Poisson processes techniques and abuse notation slightly by redefining FPP random variables N 1 and N 2 differently but analogously for each scenario, to avoid verboseness. We start with deriving the probability that event C 1 occurs (at least once) with u > s,
and
so that N 2 (σ, t s ) is a FPP and the probability generating function (PGF) of N 2 (σ, t s ) is
Similarly,
Lastly, we define
Next, let M (τ, t s ) be the number of preinitiated cells after BE onset at time τ that result in
where M i (τ, σ i , t s ) = 1 ⇐⇒ C 1 ≥ 1 ∪ (C 2 ≥ 1, C 3 ≥ 1). Due to the mutual exclusivity of these events, we have that M i (τ, σ i , t s ) = 1 with probability
Finally, we solve for our integrand of interest from Eq. (40)
With this, we have analytically solved for all components of the optimality criterion for Strategy 3 from Continuing from the Main Text we derive the following for optimal time for surveillance given Outcome 1 (negative for precursor),
Then for Outcome 2 (positive for precursor) we defined a risk associated with a surveillance timing as,
Here we derive this risk associated with next surveillance time given a certain screening result, R C|SR (t s2 ), as general lifetime risk without other cause mortality for use in optimization/cost-effectiveness analysis. Once again, for the scenario with a perfectly sensitive screen that can detect single cells, we may derive this probability using a filtered Poisson approach analogous to the approach used in Strategy 2 for a single screen. We redefine (for sake of retaining simpler notation) N (σ, t s2 ) to be the number of initiated P cells from a P * cell born at time σ that result in a clinically detected EAC clone at time t s2
where N l (σ, s l , t s2 ) = 1 if initiation at time s l produces EAC at time t s2 , and t s1 < s l < t s2 , with probability
Clinical EAC cumulative distribution, p C (s l , t s2 ), can be solved via the Kolmogorov equations of the MSCE-EAC branching process from the PDE in Eq. (20). Specifically we have
where Φ P (1, 1, 0; s, t s2 ) is the EAC survival from a single P cell (see Eq. (16)), Y 3 (u, t s2 ) is the associated ODE (see Supplementary Methods 1) and u = t s2 − s. Next let M (τ, t s2 ) be the number of preinitiated cells after BE onset at time τ that result in detectable EAC at time t s2 . Then we have
where M i (τ, σ i , t s2 ) is, as before, binary and is equal to 1 if the preinitiated cell originting at time σ i after 773 BE onset at time τ results in a detectable EAC at time t s2 , with τ < t s1 < t s2 . Note that M i (τ, σ i , t s2 ) = 1 774 is equivalent to N (σ i , t s2 ) ≥ 1 which has the probability p 3 (σ i , t s2 ) = 1 − exp − ts 2 max(σi,ts 1 ) µ 1 p C (s, t s2 )ds .
775
Then M (τ, t s2 ) is a FPP such that
5. Adaptive screen outcome 2, strategy 1 779
As a final example of adaptive surveillance, an important clinical question to consider is, "Should we offer a one-time surveillance and when would that optimal time be?" Assuming we have an estimate τ of a patient's precursor onset time, we solve for optimal next-surveillance age t * s2 ,
= arg max ts 2
Again, we can increase or decrease w depending on how much weight we want to place on keeping the risk of 780 developing malignancy under a certain value, say . For ease of notation in this strategy, we do not include 781 the other cause mortality term Pr[T D ≥ t s2 |T D > t s1 ] that can be multiplied to the entire expression of 782 optimality criterion provided in Eq. (74) as we have done in previous strategies.
784
Let us first derive a formula for the first term of this difference based on the MSCE-EAC model construction using again a filtered Poisson process approach,
Let N (σ, t s1 , t s2 ) be the number of initiated cells from a P * cell born at time σ that result in a detectable 785 clone at time t s2 , not born before t s1 786 N (σ, t s1 , t s2 ) = l N l (σ, t s1 , t s2 , s l ),
where N l (σ, t s1 , t s2 , s l ) = 1 if initiation at time s l produces a detectable clone at time t s2 , s l > t s1 with 787 probability p 2 (s l , t s2 ) = Pr[T d P (t s2 ) = 1, T d P (t s1 ) = 0|P (s l ) = 1] > 0 if and only if s l > t s1 .
788
Then N (σ, t s1 , t s2 ) is a FPP such that 789 N (σ, t s1 , t s2 ) ∼ Poisson ts 2 max(σ,ts 1 ) µ 1 p 2 (s, t s2 ) ds .
Assuming detectability of P cells based on non-extinction at time of screening, we have the following proba-790 bility (see Eq. (37)), 791 p 2 (s, t s2 ) = 1 − β P ζ P (s, t s2 ), t s1 < s < t s2
where 792 ζ P (s, t s2 ) = e (α P −β P )(ts 2 −s) − 1 α P e (α P −β P )(ts 2 −s) − β P .
clones, with detection probability provided in Eq. (36).
794
Next let M (τ, t s2 ) be the number of preinitiated cells after BE onset at time τ that result in a detectable 795 P clone at time t s2 . Then we have that
where M i (τ, σ i , t s2 ) is, as before, binary and is equal to 1 if the preinitiated cell originting at time σ i after 797 BE onset at time τ results in a detectable EAC at time t s2 , with τ < t s1 < t s2 . Note that M i (τ, σ i , t s2 ) = 1 798 is equivalent to N (σ i , t s2 ) ≥ 1 which has the probability p 3 (σ i , t s2 ) = 1 − exp − ts 2 max(σi,ts 1 ) p 2 (s, t s2 )ds .
799
Then M (τ, t s2 ) is a FPP such that 
For the second term in Eq. (74), we will now derive 803
We define similar C 1 , C 2 , C 3 mutually exclusive scenarios of counts of initiations of different types as was utilized in initial screen Strategy 3. For each of the three scenarios, we will use filtered Poisson processes techniques and abuse notation slightly by redefining FPP random variables N 1 and N 2 variables differently but analogously for each scenario, to avoid verboseness. We start with deriving the probability that event C 1 occurs (at least once), C 1 : Let N 1 (u, t s2 , s) = 1 if T d P (t s2 , s) = 1, T d M (u, t s2 , s) = 1|P (s) = 1, M (u) = 1 (85) with probability p d 2 (s, t s2 ) · p d 1 (u, t s2 ) = (1 − β P ζ P (s, t s2 )) · (1 − β M ζ M (u, t s2 )). Then we have that 804 N 1 (t s2 , s, σ) = u N 1 (u, t s2 , s, σ) ∼ Poisson p d 2 (s, t s2 ) · ts 2 s µ 2 p d 1 (u, t s2 ) du (86) and 805 N 2 (σ, t s2 ) = l N 1 (t s2 , s l , σ)
so that N 2 (σ, t s2 ) is a FPP and the PGF of N 2 (σ, t s2 ) is 806 Ψ(x; σ, t s1 , t s2 ) = exp ts 2 max(σ,ts 1 )
where Ψ(x; s, t s2 ) is the PGF of N 1 (t s2 , s, σ) = e −λ(1−x) where λ = p d 2 (s, t s2 ) · ts 2 s µ 2 p d 1 (u, t s2 ) du. Therefore Pr[C 1 ≥ 1] = Pr[N 2 (σ, t s2 ) ≥ 1] = 1 − Pr[N 2 (σ, t s2 ) = 0] = 1 − Ψ(x = 0, t s2 ) (89) = 1 − exp ts 2 max(σ,ts 1 ) µ 1 · e −λ − 1 ds (90) Similarly, C 2 : Let N 1 (u, t s2 , s) = 1 if T d P (t s2 , s) = 1, T d M (u, t s2 , s) = 0|P (s) = 1, M (u) = 1 (91) with probability p d 2 (s, t s2 ) · (1 − p d 1 (u, t s2 )) = (1 − β P ζ P (s, t s2 )) · β M ζ M (u, t s2 ). Then we have that 807 N 1 (t s2 , s, σ) = u N 2 (u, t s2 , s, σ) ∼ Poisson p d 2 (s, t s2 ) · ts 2 s µ 2 (1 − p d 1 (u, t s2 )) du (92) and 808 N 2 (σ, t s2 ) = l N 1 (t s2 , s l , σ)
so that N 2 (σ, t s2 ) is a FPP and the PGF of N 2 (σ, t s2 ) is 809 Ψ 2 (x; σ, t s1 , t s2 ) = exp ts 2 max(σ,ts 1 )
where Ψ 2 (x; s, t s2 ) is the PGF of N 1 (t s2 , s, σ) = e −λ2(1−x) where λ 2 = p d 2 (s, t s2 ) · ts 2 s µ 2 (1 − p d 1 (u, t s2 )) du. Therefore Pr[C 2 ≥ 1] = Pr[N 2 (σ, t s2 ) ≥ 1] = 1 − Pr[N 2 (σ, t s2 ) = 0] = 1 − Ψ 2 (x = 0, t s2 )
= 1 − exp ts 2 max(σ,ts 1 ) µ 1 · e −λ2 − 1 ds .
Lastly, we define C 3 : Let N 1 (u, t s2 , s) = 1 if T d P (t s2 , s) = 0, T d M (u, t s2 , s) = 1|P (s) = 1, M (u) = 1 (97) with probability p d 2 (s, u) · (1 − p d 2 (u, t s2 )) · p d 1 (u, t s2 ) = (1 − β P ζ P (s, u)) · β P ζ P (u, t s2 ) · (1 − β M ζ M (u, t s2 )). Then 810 we have that 811 N 1 (t s2 , s, σ) = u N 1 (u, t s2 , s, σ) ∼ Poisson ts 2 s µ 2 · p 2 (s, u) · (1 − p d 2 (u, t s2 )) · p d 1 (u, t s2 ) du (98) and 812 N 2 (σ, t s2 ) = l N 1 (t s2 , s l , σ) (99) Ψ 3 (x; σ, t s1 , t s2 ) = exp ts 2 max(σ,ts 1 ) µ 1 · {Ψ 3 (x; s, t s2 ) − 1} ds (100) where Ψ 3 (x; s, t s2 ) is the PGF of N 1 (t s2 , s, σ) = e −λ3(1−x) where λ 3 = ts 2 s µ 2 · p 2 (s, u) · (1 − p d 2 (u, t s2 )) · p d 1 (u, t s2 ) du. Therefore Pr[C 3 ≥ 1] = Pr[N 2 (σ, t s2 ) ≥ 1] = 1 − Pr[N 2 (σ, t s2 ) = 0] = Ψ 3 (x = 0, t s2 )
= 1 − exp ts 2 max(σ,ts 1 ) µ 1 · e −λ3 − 1 ds .
Next, let M (τ, t s2 ) be the number of preinitiated cells after BE onset at time τ that result in
where M i (τ, σ i , t s2 ) = 1 ⇐⇒ C 1 ≥ 1 ∪ C 2 ≥ 1, C 3 ≥ 1. Due to the mutual exclusivity of these events, we have that M i (τ, σ i , t s2 ) = 1 with probability
Then M (τ, t s2 ) is a FPP such that 815 M (τ, t s2 ) ∼ Poisson ts 2 τ µ 2 · p 3 (σ, t s2 ) dσ
With these, we have analytically solved for our expression of interest from Eq. (84),
and thus have both components to compute the optimality criterion for Outcome 2: Strategy 1 from Eq. (74).
